Gilead Sciences Inc (GILD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Gilead Sciences Inc (GILD)
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Key Insights
Critical company metrics and information
Share Price
$92.13Market Cap
$114.82 BillionTotal Outstanding Shares
1.25 Billion SharesTotal Employees
18,000Dividend
$0.77 Per Share QuarterlyIPO Date
January 22, 1992SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.gilead.com
Historical Stock Splits
If you bought 1 share of GILD before September 7, 2004, you'd have 8 shares today.
Execution Date | Split Amount |
---|---|
January 28, 2013 | 2-for-1 |
June 25, 2007 | 2-for-1 |
September 7, 2004 | 2-for-1 |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $2.22 Billion |
Exchange Gains/Losses | $44.00 Million |
Net Cash Flow From Operating Activities | $4.31 Billion |
Net Cash Flow | $2.26 Billion |
Net Cash Flow From Operating Activities, Continuing | $4.31 Billion |
Net Cash Flow From Financing Activities | $-1.38 Billion |
Net Cash Flow From Investing Activities, Continuing | $-710.00 Million |
Net Cash Flow From Investing Activities | $-710.00 Million |
Net Cash Flow From Financing Activities, Continuing | $-1.38 Billion |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations Before Tax | $956.00 Million |
Gross Profit | $5.97 Billion |
Income Tax Expense/Benefit, Deferred | $-576.00 Million |
Benefits Costs and Expenses | $6.59 Billion |
Diluted Average Shares | $1.25 Billion |
Selling, General, and Administrative Expenses | $1.43 Billion |
Diluted Earnings Per Share | $1.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Revenues | $7.54 Billion |
Operating Expenses | $5.08 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $1.25 Billion |
Basic Average Shares | $1.25 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss | $1.25 Billion |
Nonoperating Income/Loss | $306.00 Million |
Income/Loss From Continuing Operations After Tax | $1.25 Billion |
Basic Earnings Per Share | $1.00 |
Costs And Expenses | $6.66 Billion |
Income Tax Expense/Benefit | $-297.00 Million |
Net Income/Loss Attributable To Parent | $1.25 Billion |
Other Operating Expenses | $3.65 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Income/Loss | $888.00 Million |
Cost Of Revenue | $1.57 Billion |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Other Current Liabilities | $9.77 Billion |
Equity Attributable To Parent | $18.48 Billion |
Other Current Assets | $12.91 Billion |
Other Non-current Liabilities | $1.16 Billion |
Assets | $54.52 Billion |
Current Liabilities | $11.72 Billion |
Current Assets | $14.78 Billion |
Wages | $1.05 Billion |
Noncurrent Liabilities | $24.41 Billion |
Long-term Debt | $23.25 Billion |
Equity | $18.39 Billion |
Other Non-current Assets | $13.81 Billion |
Liabilities And Equity | $54.52 Billion |
Inventory | $1.87 Billion |
Accounts Payable | $903.00 Million |
Fixed Assets | $5.39 Billion |
Noncurrent Assets | $39.75 Billion |
Intangible Assets | $20.55 Billion |
Liabilities | $36.13 Billion |
Equity Attributable To Noncontrolling Interest | $-84.00 Million |
Historical Dividends
Current dividend: $0.77 Per Share Quarterly
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
Nov 6, 2024 | Dec 30, 2024 | Dec 13, 2024 | $0.77 | Quarterly |
Aug 8, 2024 | Sep 27, 2024 | Sep 13, 2024 | $0.77 | Quarterly |
Apr 25, 2024 | Jun 27, 2024 | Jun 14, 2024 | $0.77 | Quarterly |
Feb 1, 2024 | Mar 28, 2024 | Mar 15, 2024 | $0.77 | Quarterly |
Nov 7, 2023 | Dec 28, 2023 | Dec 15, 2023 | $0.75 | Quarterly |
Aug 3, 2023 | Sep 28, 2023 | Sep 15, 2023 | $0.75 | Quarterly |
Apr 27, 2023 | Jun 29, 2023 | Jun 15, 2023 | $0.75 | Quarterly |
Feb 2, 2023 | Mar 30, 2023 | Mar 15, 2023 | $0.75 | Quarterly |
Oct 27, 2022 | Dec 29, 2022 | Dec 15, 2022 | $0.73 | Quarterly |
Aug 2, 2022 | Sep 29, 2022 | Sep 15, 2022 | $0.73 | Quarterly |
Feb 1, 2022 | Mar 30, 2022 | Mar 15, 2022 | $0.73 | Quarterly |
Oct 28, 2021 | Dec 30, 2021 | Dec 15, 2021 | $0.71 | Quarterly |
Jul 29, 2021 | Sep 29, 2021 | Sep 15, 2021 | $0.71 | Quarterly |
Apr 27, 2021 | Jun 29, 2021 | Jun 15, 2021 | $0.71 | Quarterly |
Feb 4, 2021 | Mar 30, 2021 | Mar 15, 2021 | $0.71 | Quarterly |
Oct 28, 2020 | Dec 30, 2020 | Dec 15, 2020 | $0.68 | Quarterly |
Jul 30, 2020 | Sep 29, 2020 | Sep 15, 2020 | $0.68 | Quarterly |
Apr 29, 2020 | Jun 29, 2020 | Jun 12, 2020 | $0.68 | Quarterly |
Feb 3, 2020 | Mar 30, 2020 | Mar 13, 2020 | $0.68 | Quarterly |
Oct 23, 2019 | Dec 30, 2019 | Dec 13, 2019 | $0.63 | Quarterly |
Jul 29, 2019 | Sep 27, 2019 | Sep 13, 2019 | $0.63 | Quarterly |
May 1, 2019 | Jun 27, 2019 | Jun 14, 2019 | $0.63 | Quarterly |
Feb 1, 2019 | Mar 28, 2019 | Mar 15, 2019 | $0.63 | Quarterly |
Oct 24, 2018 | Dec 28, 2018 | Dec 14, 2018 | $0.57 | Quarterly |
Jul 24, 2018 | Sep 27, 2018 | Sep 14, 2018 | $0.57 | Quarterly |
Apr 30, 2018 | Jun 28, 2018 | Jun 15, 2018 | $0.57 | Quarterly |
Feb 5, 2018 | Mar 29, 2018 | Mar 16, 2018 | $0.57 | Quarterly |
Oct 25, 2017 | Dec 28, 2017 | Dec 15, 2017 | $0.52 | Quarterly |
Jul 25, 2017 | Sep 28, 2017 | Sep 15, 2017 | $0.52 | Quarterly |
May 2, 2017 | Jun 29, 2017 | Jun 16, 2017 | $0.52 | Quarterly |
Feb 6, 2017 | Mar 30, 2017 | Mar 16, 2017 | $0.52 | Quarterly |
Nov 1, 2016 | Dec 29, 2016 | Dec 15, 2016 | $0.47 | Quarterly |
Jul 22, 2016 | Sep 29, 2016 | Sep 16, 2016 | $0.47 | Quarterly |
Apr 27, 2016 | Jun 29, 2016 | Jun 16, 2016 | $0.47 | Quarterly |
Feb 2, 2016 | Mar 30, 2016 | Mar 16, 2016 | $0.43 | Quarterly |
Oct 26, 2015 | Dec 30, 2015 | Dec 16, 2015 | $0.43 | Quarterly |
Jul 23, 2015 | Sep 29, 2015 | Sep 16, 2015 | $0.43 | Quarterly |
Apr 24, 2015 | Jun 29, 2015 | Jun 16, 2015 | $0.43 | Quarterly |
Related Companies
View additional S&P 500 companies similar to Gilead Sciences Inc (GILD)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.